Skip to contents

Daniel Hal Solomon, MD, MPH
Associate Physician, Brigham and Women's Hospital
Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
Rheumatology, Immunology
75 Francis Street
Boston, MA 02115

Research Email: dsolomon@partners.org

Edit Profile


Research Narrative:
            Dr. Solomon is a population scientist focusing on the epidemiology and health services of rheumatic disease. He serves as the Chief of the Section of Clinical Sciences in the Division of Rheumatology at BWH. His research work is primarily funded by the NIH, AHRQ, and foundations. He has served major roles at the American College of Rheumatology and within the osteoporosis community as well. 
His achievements in population science research focuses on three areas. First, he has been a leading investigator on the cardiovascular safety of nonsteroidal anti-inflammatory drugs (NSAIDs). He has been the first author on 12 original articles in this area, has several industry-sponsored grants and one AHRQ sponsored grant in this area, and led the American College of Rheumatology Blue Ribbon Panel to set recommendations for NSAIDs. He has given over 15 invited talks on this topic and currently serve on the Executive Committee of the largest randomized controlled trial on the cardiovascular safety of NSAIDs and selective COX-2 inhibitors.
 Second, he has focused much of his research on cardiovascular manifestations of rheumatoid arthritis and its treatment. He completed one NIH grant on this topic and have another current NIH grant to study insulin and glucose metabolism in rheumatoid arthritis. He is the first author on 5 publications describing the epidemiology of cardiovascular disease in patients with rheumatoid arthritis and has given 8 invited lectures in this area.
Finally, he has helped define standards for osteoporosis care improvement. He has received two NIH grants in this area. A current NIH funded study is a large-scale adherence improvement trial for osteoporosis medications. He has first authored 8 original articles in this area and given 10 invited lectures on osteoporosis improvement. He serves on the steering committee of the National Action Plan for Bone Health, focusing on methods to improve dissemination of proven improvement methods, as well as on the American Orthopaedic Association’s Own the Bone Program.
               He teaches and mentors primarily in rheumatic disease epidemiology and pharmacoepidemiology.   He has mentored over 25 fellows and trainees and have a K24 award from NIH with 25% effort devoted to research training and mentoring. He developed and directed a course in clinical research for rheumatologists. As well, he teaches residents in the BWH Department of Medicine’s lecture series and journal club.

Investigative Interests:  drug safety and effectiveness


Education:
Harvard School of Public Health, 1998, MPH
Yale School of Medicine, 1992, MD

Honors/Awards:
American College of Rheumatology Young Investigator Award
NIH Mentoring Award
Chief, Section of Clinical Sciences, Rheumatology
Co-Director, Patient-Centered Research Center

Publications (Pulled from Harvard Catalyst Profiles):

1. Bucala RJ, Solomon DH. Trust in Publication: Now More than Ever. Arthritis Rheumatol. 2019 Mar 12.

2. Bursill D, Taylor WJ, Terkeltaub R, Kuwabara M, Merriman TR, Grainger R, Pineda C, Louthrenoo W, Edwards NL, Andrés M, Vargas-Santos AB, Roddy E, Pascart T, Lin CT, Perez-Ruiz F, Tedeschi SK, Kim SC, Harrold LR, McCarthy G, Kumar N, Chapman PT, Tausche AK, Vazquez-Mellado J, Gutierrez M, da Rocha Castelar-Pinheiro G, Richette P, Pascual E, Fisher MC, Burgos-Vargas R, Robinson PC, Singh JA, Jansen TL, Saag KG, Slot O, Uhlig T, Solomon DH, Keenan RT, Scire CA, Biernat-Kaluza E, Dehlin M, Nuki G, Schlesinger N, Janssen M, Stamp LK, Sivera F, Reginato AM, Jacobsson L, Lioté F, Ea HK, Rosenthal A, Bardin T, Choi HK, Hershfield MS, Czegley C, Choi SJ, Dalbeth N. Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. Arthritis Care Res (Hoboken). 2019 Mar; 71(3):427-434.

3. Yoshida K, Solomon DH, Haneuse S, Kim SC, Patorno E, Tedeschi SK, Lyu H, Franklin JM, Stürmer T, Hernández-Díaz S, Glynn RJ. Multinomial Extension of Propensity Score Trimming Methods: A Simulation Study. Am J Epidemiol. 2019 Mar 01; 188(3):609-616.

4. Solomon DH, Shao M, Wolski K, Nissen S, Husni ME, Paynter N. Derivation and Validation of a Major Toxicity Risk Score Among NSAID Users Based on Data from a Randomized Controlled Trial. Arthritis Rheumatol. 2019 Feb 23.

5. Zhao S, Yoshida K, Jones GT, Hughes DM, Tedeschi SK, Lyu H, Moots RJ, Solomon DH, Goodson NJ. The impact of smoking on response to TNF inhibitors in axial spondyloarthritis: methodological considerations for longitudinal observational studies. Arthritis Care Res (Hoboken). 2019 Feb 14.

6. Ford JA, Solomon DH. Challenges in Implementing Treat-to-Target Strategies in Rheumatology. Rheum Dis Clin North Am. 2019 Feb; 45(1):101-112.

7. Desai RJ, Jin Y, Franklin PD, Lee YC, Bateman BT, Lii J, Solomon DH, Katz JN, Kim SC. Association of geography and access to healthcare providers with long term prescription opioid use in Medicare patients with severe osteoarthritis: A cohort study. Arthritis Rheumatol. 2019 Jan 28.

8. Pawar A, Desai RJ, Solomon DH, Santiago Ortiz AJ, Gale S, Bao M, Sarsour K, Schneeweiss S, Kim SC. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann Rheum Dis. 2019 Apr; 78(4):456-464.

9. Lyu H, Yoshida K, Tedeschi SK, Zhao S, Xu C, Nigwekar SU, Leder BZ, Solomon DH. Intervals between bone mineral density testing with dual-energy X-ray absorptiometry scans in clinical practice. Osteoporos Int. 2019 Jan 24.

10. Lillegraven S, Greenberg JD, Reed GW, Saunders K, Curtis JR, Harrold L, Hochberg MC, Pappas DA, Kremer JM, Solomon DH. Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. PLoS One. 2019; 14(1):e0210459.